Clinical Trials Directory

Trials / Unknown

UnknownNCT01198808

Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker

Prospective Characterization of Tumor-specific T-cell Immunity in Muscle-invasive Bladder Cancer and Its Correlation With Clinical Parameters

Status
Unknown
Phase
Study type
Observational
Enrollment
50 (estimated)
Sponsor
Technical University of Munich · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Accepted

Summary

Bladder cancer is generally susceptible to immunotherapeutic measures. The investigators will characterize 40 patients with muscle-invasive bladder cancer regarding the existence and frequency of tumorspecific T-cells and regulatory T cells. The found data will be correlated to clinical data such as the cancer-specific survival and the response to chemotherapy. It is hypothesized that those patients with a high number of Tregs and no tumor-specific T-cells have a worse prognosis.

Conditions

Timeline

Start date
2010-08-01
Primary completion
2011-12-01
First posted
2010-09-10
Last updated
2012-01-18

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT01198808. Inclusion in this directory is not an endorsement.

Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker (NCT01198808) · Clinical Trials Directory